Bausch Health Companies Inc (TSE:BHC) – Research analysts at Piper Jaffray Companies upped their FY2018 earnings per share estimates for Bausch Health Companies in a research note issued on Tuesday, November 6th. Piper Jaffray Companies analyst D. Amsellem now anticipates that the company will earn $5.11 per share for the year, up from their prior estimate of $4.63. Piper Jaffray Companies also issued estimates for Bausch Health Companies’ Q2 2019 earnings at $1.37 EPS, FY2019 earnings at $5.35 EPS and FY2020 earnings at $5.45 EPS.
Separately, Cantor Fitzgerald reissued an “overweight” rating on shares of Bausch Health Companies in a research report on Wednesday, August 8th.
Bausch Health Companies (TSE:BHC) last issued its quarterly earnings data on Tuesday, August 7th. The company reported C$1.20 earnings per share (EPS) for the quarter, topping the Thomson Reuters’ consensus estimate of C$1.05 by C$0.15. The company had revenue of C$2.75 billion for the quarter, compared to the consensus estimate of C$2.67 billion.
Bausch Health Companies Company Profile
Bausch Health Companies Inc develops, manufactures, and markets a range of pharmaceutical, medical device, and over-the-counter products primarily in the therapeutic areas of eye health, gastroenterology, and dermatology. It offers dermatology products that treat a range of conditions, including actinic keratosis, acne, atopic dermatitis, psoriasis, cold sores, athlete's foot, nail fungus, and other dermatoses, as well as provides aesthetic medical devices, which address various conditions, including facial wrinkles, acne, pigmentation conditions, body sculpting, skin tightening, and laser hair removal.
Further Reading: Google Finance Portfolio Workaround
Receive News & Ratings for Bausch Health Companies Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Bausch Health Companies and related companies with MarketBeat.com's FREE daily email newsletter.